# Why Haven’t We Cured Cancer Yet? | Dr. Bob Liu Explains

Page: https://stenobird.com/podcast/biotalk-unzipped-6702602/why-haven-t-we-cured-cancer-yet-dr-bob-liu-explains
Text version: https://stenobird.com/podcast/biotalk-unzipped-6702602/why-haven-t-we-cured-cancer-yet-dr-bob-liu-explains.md
Podcast: [BioTalk Unzipped](https://stenobird.com/podcast/biotalk-unzipped-6702602)
Published: 2026-03-19T18:50:00+00:00
Episode link: https://biotalk-unzipped.captivate.fm/episode/why-havent-we-cured-cancer-immunotherapy-bob-liu
Audio file: https://episodes.captivate.fm/episode/984ab2c2-e0cb-44e4-9743-60e60f3355dd.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/biotalk-unzipped-6702602/episodes/why-haven-t-we-cured-cancer-yet-dr-bob-liu-explains
Duration seconds: 3616

## Resource

Why haven’t we cured cancer yet? A Genentech scientist explains the real reason. In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Bob Liu, Senior Principal Scientist at Genentech Roche, to unpack one of the most important and misunderstood questions in modern medicine. This is a rigorous, scientifically grounded conversation on cancer biology, immunotherapy, and the real constraints shaping oncology drug development today. Dr. Liu brings over a decade of experience across antibody drug conjugates (ADCs), bispecific antibodies, and CAR-T therapies, offering a rare, insider perspective on why a universal cure remains elusive and where meaningful progress is actually being made. Thanks to our Founding Sponsor: LEUCENTRA : Helping teams evaluate, implement, and get real value from IT solutions that support innovation, not slow it down. https://leucentra.com/ What You’ll Learn Why cancer is not one disease, but more than 200 biologically distinct conditions What “curing cancer” actually means in clinical oncology How immunotherapies like checkpoint inhibitors and CAR-T are changing outcomes The biological limits of eliminating every cancer cell How tumors evade immune detection and adapt over time Why only about 20% of patients respond to immuno-oncology therapies The role of biomarkers, molecular profiling, and precision medicine Why early detection remains one of the biggest unsolved challenges The economic and regulatory pressures shaping next-generation therapies Key Insight Cancer is not simply something to eliminate. It is a dynamic, adaptive system evolving within the human body. The future of oncology is not just eradication, but control, personalization, and intelligent engagement of the immune system. Notable Quotes “Cance…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/biotalk-unzipped-6702602/episodes/why-haven-t-we-cured-cancer-yet-dr-bob-liu-explains/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/biotalk-unzipped-6702602/why-haven-t-we-cured-cancer-yet-dr-bob-liu-explains.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.